Alberto Benussi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6560454/publications.pdf

Version: 2024-02-01

104 papers	3,342 citations	159358 30 h-index	189595 50 g-index
110 all docs	110 docs citations	110 times ranked	4270 citing authors

#	Article	IF	Citations
1	Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology, 2020, 95, e910-e920.	1.5	194
2	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
3	Phenotypic heterogeneity of Niemannâ€“Pick disease type C in monozygotic twins. Journal of Neurology, 2015, 262, 642-647.	1.8	156
4	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
5	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clinical Infectious Diseases, 2021, 73, e3019-e3026.	2.9	131
6	<scp>M</scp>ild cognitive impairment in Parkinson's disease is improved by transcranial direct current stimulation combined with physical therapy. Movement Disorders, 2016, 31, 715-724.	2.2	119
7	Long term clinical and neurophysiological effects of cerebellar transcranial direct current stimulation in patients with neurodegenerative ataxia. Brain Stimulation, 2017, 10, 242-250.	0.7	102
8	Cerebellar transcranial direct current stimulation in patients with ataxia: A double-blind, randomized, sham-controlled study. Movement Disorders, 2015, 30, 1701-1705.	2.2	100
9	Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia. Neurology, 2017, 89, 665-672.	1.5	95
10	Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 960-967.	0.9	93
11	Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. Frontiers in Aging Neuroscience, 2015, 7, 171.	1.7	90
12	Clinical Presentation and Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2â€“Related Encephalitis: The ENCOVID Multicenter Study. Journal of Infectious Diseases, 2021, 223, 28-37.	1.9	87
13	Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia. Clinical Neurophysiology, 2021, 132, 2568-2607.	0.7	85
14	Cerebello-spinal tDCS in ataxia. Neurology, 2018, 91, e1090-e1101.	1.5	78
15	Exposure to gamma tACS in Alzheimerâ€™s disease: A randomized, double-blind, sham-controlled, crossover, pilot study. Brain Stimulation, 2021, 14, 531-540.	0.7	67
16	Csf p-tau₁₈₁/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 86-91.	1.1	65
17	Classification Accuracy of Transcranial Magnetic Stimulation for the Diagnosis of Neurodegenerative Dementias. Annals of Neurology, 2020, 87, 394-404.	2.8	65
18	Variability and Predictors of Response to Continuous Theta Burst Stimulation: A TMS-EEG Study. Frontiers in Neuroscience, 2018, 12, 400.	1.4	64

#	Article	IF	Citations
19	Toward a Glutamate Hypothesis of Frontotemporal Dementia. Frontiers in Neuroscience, 2019, 13, 304.	1.4	59
20	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 77, 1129-1141.	1.2	55
21	Impaired longâ€term potentiationâ€“like cortical plasticity in presymptomatic genetic frontotemporal dementia. Annals of Neurology, 2016, 80, 472-476.	2.8	48
22	Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19. Neurobiology of Stress, 2021, 14, 100326.	1.9	48
23	Diagnosis of Mild Cognitive Impairment Due to Alzheimerâ€™s Disease with Transcranial Magnetic Stimulation. Journal of Alzheimer's Disease, 2018, 65, 221-230.	1.2	44
24	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	2.8	42
25	Discrimination of atypical parkinsonisms with transcranial magnetic stimulation. Brain Stimulation, 2018, 11, 366-373.	0.7	40
26	Clinical and biomarker changes in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 76, 133-140.	1.5	39
27	Non-Invasive Cerebellar Stimulation in Neurodegenerative Ataxia: A Literature Review. International Journal of Molecular Sciences, 2020, 21, 1948.	1.8	39
28	Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia. Brain, 2021, 144, 2310-2321.	3.7	38
29	Increasing Brain Gamma Activity Improves Episodic Memory and Restores Cholinergic Dysfunction in Alzheimer's Disease. Annals of Neurology, 2022, 92, 322-334.	2.8	38
30	The impact of transcranial magnetic stimulation on diagnostic confidence in patients with Alzheimer disease. Alzheimer's Research and Therapy, 2018, 10, 94.	3.0	37
31	Classification accuracy of TMS for the diagnosis of mild cognitive impairment. Brain Stimulation, 2021, 14, 241-249.	0.7	35
32	Anti-GluA3 antibodies in frontotemporal dementia: effects on glutamatergic neurotransmission and synaptic failure. Neurobiology of Aging, 2020, 86, 143-155.	1.5	34
33	Natural history and predictors of survival in progressive supranuclear palsy. Journal of the Neurological Sciences, 2017, 382, 105-107.	0.3	32
34	TMS for staging and predicting functional decline in frontotemporal dementia. Brain Stimulation, 2020, 13, 386-392.	0.7	31
35	Mild Cognitive Impairment and Progression to Dementia in Progressive Supranuclear Palsy. Neurodegenerative Diseases, 2017, 17, 286-291.	0.8	30
36	Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin. Journal of Alzheimer's Disease, 2018, 62, 1113-1123.	1.2	29

#	Article	IF	Citations
37	COVID-19 impact on consecutive neurological patients admitted to the emergency department. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 218-220.	0.9	28
38	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	1.4	28
39	Progression of behavioural disturbances in frontotemporal dementia: a longitudinal observational study. European Journal of Neurology, 2020, 27, 265-272.	1.7	27
40	Transcranial stimulation in frontotemporal dementia: A randomized, doubleâ€blind, shamâ€controlled trial. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12033.	1.8	27
41	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	3.7	27
42	Cerebrospinal Fluid Tau Levels Predict Prognosis in Non-Inherited Frontotemporal Dementia. Neurodegenerative Diseases, 2013, 13, 224-9.	0.8	26
43	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
44	Stimulation over the cerebellum with a regular figure-of-eight coil induces reduced motor cortex inhibition in patients with progressive supranuclear palsy. Brain Stimulation, 2019, 12, 1290-1297.	0.7	23
45	Neuroanatomical Correlates of Transcranial Magnetic Stimulation in Presymptomatic Granulin Mutation Carriers. Brain Topography, 2018, 31, 488-497.	0.8	21
46	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
47	Altered inhibitory interaction among inferior frontal and motor cortex in <scp>l</scp>â€dopaâ€induced dyskinesias. Movement Disorders, 2016, 31, 755-759.	2.2	20
48	Modulation of long-term potentiation-like cortical plasticity in the healthy brain with low frequency-pulsed electromagnetic fields. BMC Neuroscience, 2018, 19, 34.	0.8	20
49	Neurophysiological Correlates of Positive and Negative Symptoms in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 73, 1133-1142.	1.2	20
50	NMDA and AMPA Receptor Autoantibodies in Brain Disorders: From Molecular Mechanisms to Clinical Features. Cells, 2021, 10, 77.	1.8	20
51	Enhancing theory of mind in behavioural variant frontotemporal dementia with transcranial direct current stimulation. Cognitive, Affective and Behavioral Neuroscience, 2018, 18, 1065-1075.	1.0	18
52	Hyperconnectivity in Dementia Is Early and Focal and Wanes with Progression. Cerebral Cortex, 2021, 31, 97-105.	1.6	18
53	Preliminary Results on Long-Term Potentiation-Like Cortical Plasticity and Cholinergic Dysfunction After Miglustat Treatment in Niemann-Pick Disease Type C. JIMD Reports, 2017, 36, 19-27.	0.7	17
54	Mendelian forms of disease and age at onset affect survival in frontotemporal dementia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 87-92.	1.1	16

#	Article	IF	Citations
55	Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: impact on diagnostic confidence and diagnostic accuracy. Alzheimer's Research and Therapy, 2019, 11, 95.	3.0	16
56	Recent advances in understanding frontotemporal degeneration. F1000Research, 2019, 8, 2098.	0.8	16
57	Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC. F1000Research, 2018, 7, 194.	0.8	14
58	Clinical, Genetic, and Neuroimaging Features of Early Onset Alzheimer Disease: The Challenges of Diagnosis and Treatment. Current Alzheimer Research, 2014, 11, 909-917.	0.7	14
59	Sex influences clinical phenotype in frontotemporal dementia. Neurological Sciences, 2022, 43, 5281-5287.	0.9	14
60	Modulating risky decisionâ€•making in Parkinson's disease by transcranial direct current stimulation. European Journal of Neurology, 2017, 24, 751-754.	1.7	13
61	Facial feedback and autonomic responsiveness reflect impaired emotional processing in Parkinsonâ€™s Disease. Scientific Reports, 2016, 6, 31453.	1.6	11
62	Cortico-spinal tDCS in ALS: A randomized, double-blind, sham-controlled trial. Brain Stimulation, 2019, 12, 1332-1334.	0.7	11
63	Expanding the role of education in frontotemporal dementia: a functional dynamic connectivity (the) Tj ETQq1 1 0.784314 rgBT /Ove	1.5	11
64	Effects of COVIDâ€19 outbreak on stroke admissions in Brescia, Lombardy, Italy. European Journal of Neurology, 2021, 28, e4-e5.	1.7	11
65	Autoimmunity and Frontotemporal Dementia. Current Alzheimer Research, 2018, 15, 602-609.	0.7	10
66	â€œRealâ€•worldâ€•eligibility for aducanumab depends on clinical setting and patients' journey. Journal of the American Geriatrics Society, 2022, 70, 626-628.	1.3	10
67	Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 87, 991-997.	1.2	10
68	Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. Neurological Sciences, 2015, 36, 751-757.	0.9	9
69	Clinical and neurophysiological characteristics of heterozygousNPC1carriers. JIMD Reports, 2019, 49, 80-88.	0.7	9
70	Neurotransmitter imbalance dysregulates brain dynamic fluidity in frontotemporal degeneration. Neurobiology of Aging, 2020, 94, 176-184.	1.5	9
71	State-of-the-Art Methods and Emerging Fluid Biomarkers in the Diagnostics of Dementiaâ€”A Short Review and Diagnostic Algorithm. Diagnostics, 2021, 11, 788.	1.3	9
72	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	4.4	9

#	Article	IF	Citations
73	Prodromal frontotemporal dementia: clinical features and predictors of progression. Alzheimer's Research and Therapy, 2021, 13, 188.	3.0	8
74	Impact of SARS-CoV-2 on reperfusion therapies for acute ischemic stroke in Lombardy, Italy: the STROKOVID network. Journal of Neurology, 2021, 268, 3561-3568.	1.8	7
75	Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration. Journal of Experimental Pharmacology, 2021, Volume 13, 359-376.	1.5	7
76	Cortical Inhibitory Imbalance in Functional Paralysis. Frontiers in Human Neuroscience, 2020, 14, 153.	1.0	6
77	GluA3 autoantibodies induce alterations in dendritic spine and behavior in mice. Brain, Behavior, and Immunity, 2021, 97, 89-101.	2.0	6
78	Author response: Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trial. Neurology, 2019, 92, 1122-1122.	1.5	5
79	Cortical network modularity changes along the course of frontotemporal and Alzheimer's dementing diseases. Neurobiology of Aging, 2022, 110, 37-46.	1.5	5
80	Neurophysiological Correlates of Motor and Cognitive Dysfunction in Prodromal and Overt Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2022, 86, 579-588.	1.2	5
81	Transcranial Magnetic Stimulation in AlzheimerÃƒÂ¢Ã‚Â€Ã‚Â™s Disease and Cortical Dementias. , 2015, 05, .		4
82	Multimodal Brain Analysis of Functional Neurological Disorders: A Functional Stroke Mimic Case Series. Psychotherapy and Psychosomatics, 2017, 86, 317-319.	4.0	4
83	Embedded platform-based system for early detection of Alzheimer disease through transcranial magnetic stimulation. , 2018, , .		4
84	Clinical and radiological features of posterior cortical atrophy (PCA) in a GRN mutation carrier: a case report. European Journal of Neurology, 2021, 28, 344-348.	1.7	4
85	Modifiable potential risk factors in familial and sporadic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 1195-1205.	1.7	4
86	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	1.5	3
87	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	1.2	3
88	Clinical outcome of neurological patients with COVID-19: the impact of healthcare organization improvement between waves. Neurological Sciences, 2022, 43, 2923-2927.	0.9	3
89	Diagnosing Progressive Supranuclear Palsy: Role of Biological and Neuroimaging Markers. , 2014, 04, .		2
90	Prevalence of cerebrospinal fluid Alzheimer disease-like pattern in atypical dementias. Advances in Alzheimer's Disease, 2012, 01, 45-50.	0.3	2

#	Article	IF	Citations
91	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	1.1	2
92	Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimerâ€™s Disease. Neurology International, 2022, 14, 357-367.	1.3	2
93	[P2â€“222]: SENSITIVITY AND SPECIFICITY OF TRANSCRANIAL MAGNETIC STIMULATION FOR DIFFERENTIAL DIAGNOSIS OF ALZHEIMER's DISEASE AND FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P695.	0.4	1
94	The impact of TMS on the differential diagnosis and progression of dementia. Brain Stimulation, 2019, 12, 504.	0.7	1
95	Cortical Circuitry and Synaptic Dysfunctions in Alzheimerâ€™s Disease and Other Dementias. Neural Plasticity, 2021, 2021, 1-3.	1.0	1
96	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
97	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	1.7	1
98	P2-099: CSF P-TAU181/TAU RATIO TO DISTINGUISH FTLD-TDP FROM FTLD-TAU. , 2014, 10, P507-P507.		0
99	Response to comments on natural history and predictors of survival in progressive supranuclear palsy. Journal of the Neurological Sciences, 2018, 385, 235-236.	0.3	0
100	Central pontine myelinolysis as a consequence of hyperemesis gravidarum: A case report. Journal of the Neurological Sciences, 2021, 429, 118606.	0.3	0
101	Prediction of cognitive decline in subjects with subjective memory impairment. Journal of the Neurological Sciences, 2021, 429, 118983.	0.3	0
102	Eligibility for disease-modifying treatment in Alzheimer's disease: Evidence from an observational study over 4 years. Journal of the Neurological Sciences, 2021, 429, 118982.	0.3	0
103	Dissemination in time and space in presymptomatic granulin mutation carriers: A GENFI dynamic functional network connectivity study. Journal of the Neurological Sciences, 2021, 429, 117779.	0.3	0
104	Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study. Frontiers in Neurology, 0, 13, .	1.1	0